- Home
- AIRS vs TLSI Comparison
AIRS vs TLSI Comparison
Compare AIRS & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- TLSI
- Stock Information
- Founded
- AIRS 2012
- TLSI 2010
- Country
- AIRS United States
- TLSI United States
- Employees
- AIRS N/A
- TLSI N/A
- Industry
- AIRS Medical/Nursing Services
- TLSI Medical Specialities
- Sector
- AIRS Health Care
- TLSI Health Care
- Exchange
- AIRS Nasdaq
- TLSI Nasdaq
- Market Cap
- AIRS 166.3M
- TLSI 150.0M
- IPO Year
- AIRS 2021
- TLSI N/A
- Fundamental
- Price
- AIRS $6.20
- TLSI $4.43
- Analyst Decision
- AIRS Hold
- TLSI Strong Buy
- Analyst Count
- AIRS 3
- TLSI 5
- Target Price
- AIRS $3.75
- TLSI $10.90
- AVG Volume (30 Days)
- AIRS 515.3K
- TLSI 107.9K
- Earning Date
- AIRS 11-07-2025
- TLSI 11-13-2025
- Dividend Yield
- AIRS N/A
- TLSI N/A
- EPS Growth
- AIRS N/A
- TLSI N/A
- EPS
- AIRS N/A
- TLSI N/A
- Revenue
- AIRS $165,109,000.00
- TLSI $35,990,000.00
- Revenue This Year
- AIRS N/A
- TLSI $56.79
- Revenue Next Year
- AIRS $5.14
- TLSI $54.15
- P/E Ratio
- AIRS N/A
- TLSI N/A
- Revenue Growth
- AIRS N/A
- TLSI 45.50
- 52 Week Low
- AIRS $1.53
- TLSI $3.42
- 52 Week High
- AIRS $9.20
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- AIRS 50.13
- TLSI 41.24
- Support Level
- AIRS $5.73
- TLSI $4.80
- Resistance Level
- AIRS $6.39
- TLSI $5.10
- Average True Range (ATR)
- AIRS 0.36
- TLSI 0.28
- MACD
- AIRS -0.04
- TLSI -0.06
- Stochastic Oscillator
- AIRS 40.17
- TLSI 2.17
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. Elite Body Sculpture, provides custom body contouring using the proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure. The company has one operating and reportable segment, direct medical procedure services.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.